18F-FDG PET/CT for the Diagnosis of Malignant and Infectious Complications After Solid Organ Transplantation

다국어 초록 (Multilingual Abstract)

Purpose Infection and malignancy represent two common complications after solid organ transplantation, which are often characterized by poorly specific clinical symptomatology.
Herein, we have evaluated the role of 18F-fluoro-2-deoxy-Dglucose (FDG) positron emission tomography/computed tomography (PET/CT) in this clinical setting.
Methods Fifty-eight consecutive patients who underwent FDG PET/CT after kidney, lung or heart transplantation were included in this retrospective analysis. Twelve patients underwent FDGPET/CT to strengthen or confirma diagnostic suspicion of malignancies. The remaining 46 patients presented with unexplained inflammatory syndrome, fever of unknown origin (FUO), CMVor EBV seroconversion during post-transplant follow-up without conclusive conventional imaging. FDG PET/CT results were compared to histology or to the finding obtained during a clinical/imaging follow-up period of at least 6 months after PET/CT study.
Results Positive FDG PET/CT results were obtained in 18 (31 %) patients. In the remaining 40 (69 %) cases, FDG PET/CT was negative, showing exclusively a physiological radiotracer distribution. On the basis of a patient-based analysis, FDG PET/CT’s sensitivity, specificity, PPV and NPV were respectively 78 %, 90 %, 78 % and 90 %, with a global accuracy of 86 %.
FDG PET/CT was true positive in 14 patients with bacterial pneumonias (n = 4), pulmonary fungal infection (n = 1), histoplasmosis (n = 1), cutaneous abscess (n = 1), inflammatory disorder (sacroiliitis) (n = 1), lymphoma (n = 3) and NSCLC (n = 3). On the other hand, FDG PET/CT failed to detect lung bronchoalveolar adenocarcinoma, septicemia, endocarditis and graft-versus-host disease (GVHD), respectively, in four patients. FDG PET/CT contributed to adjusting the patient therapeutic strategy in 40 % of cases.
Conclusions FDG PET/CT emerges as a valuable technique to manage complications in the post-transplantation period.
FDG PET/CT should be considered in patients with severe unexplained inflammatory syndrome or FUO and inconclusive conventional imaging or to discriminate active from silent lesions previously detected by conventional imaging particularly when malignancy is suspected.

참고문헌 (Reference)

1 Mamede M, "[18F]FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung" 7 : 369-379, 2005

2 Federici L, "Value of(18)F-FDG-PET/CT in patients with fever of unknown origin and unexplained prolonged inflammatory syndrome : a single centre analysis experience" 64 : 55-60, 2010

3 Okumura W, "Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis" 45 : 1989-1998, 2004

4 Guy SD, "Use of FDG PET/CT for investigation of febrile neutropenia : evaluation in high-risk cancer patients" 39 : 1348-1355, 2012

5 Sathekge M, "Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis" 52 : 880-885, 2011

6 Jigang Yang HZ, "The role of 18F-FDG PET/CT in the evaluation of pediatric transplant patients" 18-, 2015

7 Seltzer MA, "The impact of PET on the management of lung cancer : the referring physician’s perspective" 43 : 752-756, 2002

8 Tsao L, "The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders" 131 : 1209-1218, 2007

9 Dierickx D, "The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder" 98 : 771-775, 2013

10 Imperiale A, "Simultaneous 18F-FDOPA PET/CT-guided biopsy and radiofrequency ablation of recurrent neuroendocrine hepatic metastasis:further step toward a theranostic approach" 2015

11 Eiro M, "Risk factors for bleeding complications in percutaneous renal biopsy" 9 : 40-45, 2005

12 Bakker NA, "Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation" 20 : 207-218, 2007

13 Caillard S, "Post-transplantation lymphoproliferative disorder after kidney transplantation : report of a nationwide French registry and the development of a new prognostic score" 31 : 1302-1309, 2013

14 Taylor AL, "Post-transplant lymphoproliferative disorders(PTLD)after solid organ transplantation" 56 : 155-167, 2005

15 von Falck C, "Post transplant lymphoproliferative disease in pediatric solid organ transplant patients : a possible role for [18F]-FDGPET(/CT)in initial staging and therapy monitoring" 63 : 427-435, 2007

16 Wiener RS, "Populationbased risk for complications after transthoracic needle lung biopsy of a pulmonary nodule : an analysis of discharge records" 155 : 137-144, 2011

17 Cornelis F, "Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities" 41 : 2265-2272, 2014

18 Richardson CM, "Percutaneous lung biopsies : a survey of UK practice based on 5444 biopsies" 75 : 731-735, 2002

19 Townsend DW, "PET/CT today and tomorrow" 45 (45): 4S-14S, 2004

20 Poeppel TD, "PET/CT for the staging and follow-up of patients with malignancies" 70 : 382-392, 2009

21 Penn I, "Malignant tumors arising de novo in immunosuppressed organ transplant recipients" 14 : 407-417, 1972

22 Opelz G, "Lymphomas after solid organ transplantation : a collaborative transplant study report : lymphomas after solid organ transplantation" 4 : 222-230, 2004

23 Watt KDS, "Long-term probability of and mortality from de novo malignancy after liver transplantation" 137 : 2010-2017, 2009

24 Treglia G, "Is there a role for fluorine 18 fluorodeoxyglucose-positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review" 35 : 387-393, 2011

25 Shyn PB, "Interventional positron emission tomography/computed tomography : state-of-the-art" 16 : 182-190, 2013

26 Imperiale A, "Interest of [18F]FDG PET/CT for treatment efficacy assessment in aggressive phenotype of sarcoidosis with special emphasis on sinonasal involvement" 57 : 177-186, 2013

27 Yap CS, "Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer : the referring physician’s perspective" 42 : 1334-1337, 2001

28 Kubota K, "Impact of FDG-PET findings on decisions regarding patient management strategies : a multicenter trial in patients with lung cancer and other types of cancer" 29 : 431-441, 2015

29 Meta J, "Impact of 18F-FDG PET on managing patients with colorectal cancer : the referring physician’s perspective" 42 : 586-590, 2001

30 Helderman JH, "Immunosuppression : practice and trends" 3 : 41-52, 2003

31 McCormack L, "How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation? In four patients with PTLD investigated with PET/CT, this method provided new information that changed medical management in three of the four patients" 6 : 1731-1736, 2006

32 Dickson RP, "High frequency of bronchogenic carcinoma after single-lung transplantation" 25 : 1297-1301, 2006

33 Sturm E, "Fluordeoxyglucose positron emission tomography contributes to management of pediatric liver transplantation candidates with fever of unknown origin" 12 : 1698-1704, 2006

34 Kazama T, "FDG PET in the evaluation of treatment for lymphoma : clinical usefulness and pitfalls1" 25 : 191-207, 2005

35 Balink H, "F-18 FDG PET/CT in the diagnosis of fever of unknown origin" 34 : 862-868, 2009

36 Jamar F, "EANM/SNMMI guideline for 18F-FDG use in inflammation and infection" 54 : 647-658, 2013

37 Graute V, "Diagnostic role of whole-body [18F]-FDG positron emission tomography in patients with symptoms suspicious for malignancy after heart transplantation" 31 : 958-966, 2012

38 Parker A, "Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients—BCSH and BTS Guidelines : Guideline" 149 : 675-692, 2010

39 Anastasiadis A, "Complications of prostate biopsy" 13 : 829-837, 2013

40 Cohen MB, "Complications of percutaneous liver biopsy in children" 102 : 629-632, 1992

41 Kwee TC, "Combined FDG-PET/CT for the detection of unknown primary tumors : systematic review and meta-analysis" 19 : 731-744, 2009

42 Thomas JA, "Clinicopathologic implications of Epstein-Barr virus related B cell lymphoma in immunocompromised patients" 48 : 287-, 1995

43 Vajdic CM, "Cancer incidence and risk factors after solid organ transplantation" 125 : 1747-1754, 2009

44 Dong M, "Ameta-analysis of the value of fluorodeoxyglucose-PET/PET-CT in the evaluation of fever of unknown origin" 80 : 834-844, 2011

45 Humar A, "AST ID working group on infectious disease monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation" 6 : 262-274, 2006

46 Mahillo B, "2009 global data in organ donation and transplantation : activities, laws, and organization" 92 : 1069-1074, 2011

47 Panagiotidis E, "18F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder" 55 : 515-519, 2013

48 Braun JJ, "18F-FDG PET/CT in sarcoidosis management : review and report of 20 cases" 35 : 1537-1543, 2008